April 2026 FDA Recall Claravis by Teva Pharmaceuticals Usa, Inc
D-0521-2026 - Failed Impurities/Degradation Specifications

This Class II drug recall was voluntarily initiated by Teva Pharmaceuticals Usa, Inc on April 6, 2026 for the product Claravis. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0521-2026

Reason for Recall
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
Initiated
04-06-2026
Reported
04-29-2026
Quantity
5,101 cartons

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Teva Pharmaceuticals USA, Inc
Nationwide in the USA, Puerto Rico and Virgin Islands
Claravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, NDC 0555-1054-56, with 10x10 blister packs NDC 0555-1054-60; b) 30-count carton, NDC 0555-1054-86, with 3X10 blister pack NDC 0555-1054-60; Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.

Batch or Lot Expiration Information

Lot# Lots#: 100067507, 100067508, Exp 07/31/2026